JOHNSON MATTHEY INC. for JOHNSON MATTHEY INC.
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Energy/Nuclear ENG
S. 2657, American Energy Innovation Act, provisions relating to improving energy efficiency at federal buildings, incentivizing state building energy efficiency, and creating DOE grid storage programs. Potential House bills aimed at incentivizing new technologies aimed at mitigating climate change.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID CETOLA | — |
Trade (domestic/foreign) TRD
United States-Mexico-Canada (USMCA); the Uniform Tariff Schedule (UTS), including USTR's s. 301 investigation into China; Department of Commerce's s. 232 Aluminum and Steel investigation, and s. 232 Auto investigation; and potential tariffs on imports from Mexico.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID CETOLA | — |
Transportation TRA
Potential bill establishing a DOT grant program relating to national alternative-fueled vehicle charging/fuel corridors and a new commercial truck emissions demonstration program. Potential 2020 update to Fixing America's Surface Transportation Act of 2015 relating to low-emission commercial truck incentives.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID CETOLA | — |
Taxation/Internal Revenue Code TAX
Potential bill that would revise the federal excise tax on commercial truck purchases based on a truck's performance beyond currently applicable emission standards. S. 1094 and H.R. 2256, Driving America Forward Act, provisions relating to the extension of the electric vehicle tax credit. S. 2289 and H.R. 3961, Renewable Energy Extension Act of 2019, provisions relating to extension of tax incentives associated with fuel cell projects.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID CETOLA | — |
Budget/Appropriations BUD
H.R. 1865, Further Consolidated Appropriations Act of 2020, FY2020 appropriations provisions relating to the general funding levels of the EPA, delaying implementation of the 2015 Ozone NAAQS, funding regulatory work for EPA's Cleaner Trucks Initiative, extending alternative-fueled vehicle tax credits, funding DOE fuel cell-related research and development programs, enhancing first generic drug manufacturers' 180-day exclusivity protections, and process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers. H.R. 478, Coronavirus Aid, Relief, and Economic Security Act, provisions relating to drug manufacturers to submit more information when there is an interruption in supply, including information about active pharmaceutical ingredients, when active pharmaceutical ingredients are the cause of the interruption, and potential provisions relating to the modification of China 301 tariffs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID CETOLA | — |
Environment/Superfund ENV
EPA heavy-duty vehicle criteria pollutant regulation (EPA Cleaner Trucks Initiative). EPA heavy-duty vehicle GHG Phase 2 regulation, provisions relating to glider kits. EPA and NHTSA federal light-duty mobile source regulations, provisions relating to criteria pollutant emission standards, CAFE and greenhouse gas programs, and certification procedures. EPA reconsideration of the 2015 Ozone NAAQS and the 2020 Ozone NAAQS review. H.R. 978, Clean and Efficient Cars Act of 2019, provisions relating to EPA/NHTSA light-duty greenhouse gas and fuel efficiency standards. S. 2302, America's Transportation Infrastructure Act of 2019, provisions relating to Diesel Emissions Reduction Act funding and alternative fuel/recharging infrastructure funding.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID CETOLA | — |
Government Issues GOV
H.R. 1, For the People Act of 2019, provisions relating to changes to the framework governing commercial lobbying and the definition of "foreign national" for the purposes of participating in the political process. H.R. 5150, Transparency in Government Act of 2019, provisions related to amending the Lobbying Disclosure Act exemption under the Foreign Agents Registration Act. H.R. 5733, Foreign Influence Registration Modernization Act, provisions relating to excluding agents of foreign enterprises that are not under the control or direction of a government of a foreign country or a foreign political party from FARA. S. 1762, Foreign Agents Disclosure and Registration Enhancement Act of 2019, provisions relating to directing the GAO to conduct audits of the use of the LDA exemption and the expansion of the Department of Justice's authority to enforce the Foreign Agents Registration Act and increase noncompliance penalties.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID CETOLA | — |
Pharmacy PHA
H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic drug manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 3, Lower Drug Costs Now Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 19, Lower Costs, More Cures Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drug manufacturers.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID CETOLA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.